Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Treatment of Germline BRCA with PARP and Checkpoint

July 16th 2019

The Use of Chemotherapy and Checkpoint Inhibitors for TNBC

July 16th 2019

Immunotherapy for Triple-Negative Breast Cancer

July 16th 2019

Approach to Neoadjuvant Therapy for Triple-Negative Breast Cancer

July 16th 2019

Emerging Agents for Relapsed-Refractory HER2+ MBC

July 16th 2019

Treatment Options for Metastatic HER2+ Breast Cancer

July 16th 2019

Treatment of Homogeneous Tumors vs Heterogenetic Tumors

July 16th 2019

Trials That Shaped HER2-Positive Therapy for BC

July 16th 2019

TAILORx Trial for ER-Positive Patients

July 16th 2019

Implications of Finding Patients With PIK3CA Mutations

July 16th 2019

Treatment After Progression on CDK4/6

July 16th 2019

Predictive and Prognostic Biomarkers and Resistance Mutations

July 16th 2019

MONALEESA-2 and Choosing Among the CDK4/6

July 16th 2019

Introduction and Overview of the MONALEESA-7 Trial

July 16th 2019

Dr. Papadimitrakopoulou on Benefits of Liquid Biopsy Versus Standard Tissue in Lung Cancer

July 16th 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the benefits of liquid biopsy compared with standard tissue in lung cancer.

Expert Highlights Need for Widespread Liquid Biopsy Use in Lung Cancer Treatment

July 15th 2019

Alain Borczuk, MD, discusses the recent advancements in lung cancer treatment, the evolving field, and the future potential for liquid biopsies.

Blood-Based Markers Key to Precision Medicine Approach in Breast Cancer

July 9th 2019

Mark E. Burkard, MD, PhD, discussed the significance of utilizing markers in the blood and highlighted emerging actionable mutations in breast cancer.

Genome Sequencing Studies Shake Up Views on the Cancer Mutation Landscape

July 2nd 2019

Emerging findings from the most expansive studies of tumor genomes ever conducted are building a case for integrating all aspects of germline and somatic mutations into the analytical paradigm as a logical next step for precision oncology.

Genomic Profiling Confirms MAPK/ERK Gene Alterations in Metastatic Prostate Cancer

June 27th 2019

MAPK/ERK gene alterations, primarily receptor tyrosine kinases, BRAF, and CDK4/6 amplifications, were found to be present in more than half of patients with heavily pretreated metastatic prostate cancer.

Dr. Papadimitrakopoulou on Distinguishing Features of the Guardant360 Assay in Lung Cancer

June 19th 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, discusses distinguishing features of the Guardant360 assay in non–small cell lung cancer (NSCLC).